February 2014
BioWorld Today;2/6/2014, Vol. 25 Issue 25, p3
The article reports on the 30.5-million-dollar net sales achieved by Gen mab A/S's anti-CD20 antibody Arzerra (ofatumumab) in the fourth quarter of 2013.


Related Articles

  • Arzerra net sales in Q2 2012 were GBP 14.9 million.  // Biotech Financial Reports;Aug2012, Vol. 19 Issue 8, p6 

    The article reports on the net sales of Copenhagen, Denmark-based biotechnology company Genmab A/S's Arzerra (ofatumumab) in the second quarter of 2012. It states that net sales of Arzerra reached 14.9 million pounds which consists of net sales in the U.S. of 9.4 million pounds and 5.5 million...

  • Genmab Still Cutting: 300 Jobs and Manufacturing Next to Go. Morrison, Trista // BioWorld Today;11/9/2009, Vol. 20 Issue 216, p3 

    This article reports on the plan of Genmab A/S to cut 300 jobs and sell its manufacturing facility. Genmab aims to return to discovering antibodies. Piper Jaffray analyst Richard Parkes noted that the plan will remove the company's near-to-midterm financing overhang. The layoff will affect the...

  • Leukemia Update.  // PharmaWatch: Cancer;Feb2007, Vol. 6 Issue 2, p5 

    The article reports on the agreement signed between Genmab AS and GlaxoSmithKline (GSK) that could allow the Danish biotech company to earn up to $2.1 billion on the development of a leukemia treatment. Under the agreement, Genmab will receive a license fee of approximately $102 million while...

  • GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY.  // Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p6 

    Presents information on a collaborative agreement of Genmab A/S with Immunex Corporation to discover and develop an antibody against lymphoma as of November 2001.

  • GENMAB/ROCHE ANNOUNCE ANTIBODY DEVELOPMENT COLLABORATION.  // Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p7 

    Announces the broad collaboration of Genmab A/S with the Roche company for the creation and development of human antibody therapeutics.

  • GSK and Genmab submit ofatumumab application to FDA.  // Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p49 

    The article reports on the submission of a Biologics License Application to the U.S. Food and Drug Administratino (FDA) by GlaxoSmithKline and Genmab.

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Genmab A/S submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL).

  • Serono is investing in Genmab antibody.  // Chemical Market Reporter;8/22/2005, Vol. 268 Issue 6, p7 

    Reports on European biotechnology company Serono's plan to invest in Genmab AS as part of an agreement in which Serono gets exclusive worldwide rights to develop and commercialize Genmab's oncology monoclonal antibody, HuMax-CD4 (zanolimumab). Terms of the agreement; Development of the HuMax-CD4...

  • Genmab, Lundbeck Collaborate on Antibodies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the announcement of Genmab A/S regarding an agreement with H. Lundbeck A/S. that it will create and develop human antibody therapeutics for disorders of the central nervous system.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics